Robert Besthof - 08 Mar 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Interim CEO
Signature
/s/ Robert Besthof
Issuer symbol
NRXP
Transactions as of
08 Mar 2022
Net transactions value
+$261,000
Form type
4
Filing time
10 Mar 2022, 15:04:19 UTC
Previous filing
02 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Employee Stock Option Award $261,000 +100,000 +40% $2.61* 347,200 08 Mar 2022 Common Stock 100,000 $2.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc.